Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
NYSE:TEVA's Cash-to-Debt is ranked lower than
96% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. NYSE:TEVA: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:TEVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.42 Max: N/A
Current: 0.03
Equity-to-Asset 0.37
NYSE:TEVA's Equity-to-Asset is ranked lower than
82% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NYSE:TEVA: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:TEVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.49 Max: 0.6
Current: 0.37
0.36
0.6
Interest Coverage 4.08
NYSE:TEVA's Interest Coverage is ranked lower than
83% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.48 vs. NYSE:TEVA: 4.08 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:TEVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.95 Max: 19.16
Current: 4.08
3.6
19.16
Piotroski F-Score: 3
Altman Z-Score: 0.83
Beneish M-Score: -2.25
WACC vs ROIC
3.57%
2.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 8.29
NYSE:TEVA's Operating Margin % is ranked higher than
51% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NYSE:TEVA: 8.29 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:TEVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 8.29
8.12
25.46
Net Margin % 1.49
NYSE:TEVA's Net Margin % is ranked lower than
67% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. NYSE:TEVA: 1.49 )
Ranked among companies with meaningful Net Margin % only.
NYSE:TEVA' s Net Margin % Range Over the Past 10 Years
Min: 1.49  Med: 12.03 Max: 20.75
Current: 1.49
1.49
20.75
ROE % 0.24
NYSE:TEVA's ROE % is ranked lower than
68% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. NYSE:TEVA: 0.24 )
Ranked among companies with meaningful ROE % only.
NYSE:TEVA' s ROE % Range Over the Past 10 Years
Min: 0.22  Med: 10 Max: 16.18
Current: 0.24
0.22
16.18
ROA % 0.43
NYSE:TEVA's ROA % is ranked lower than
66% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NYSE:TEVA: 0.43 )
Ranked among companies with meaningful ROA % only.
NYSE:TEVA' s ROA % Range Over the Past 10 Years
Min: 0.43  Med: 4.98 Max: 9.34
Current: 0.43
0.43
9.34
ROC (Joel Greenblatt) % 14.14
NYSE:TEVA's ROC (Joel Greenblatt) % is ranked higher than
52% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. NYSE:TEVA: 14.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:TEVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.14  Med: 33.66 Max: 49.49
Current: 14.14
14.14
49.49
3-Year Revenue Growth Rate -1.60
NYSE:TEVA's 3-Year Revenue Growth Rate is ranked lower than
72% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NYSE:TEVA: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:TEVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 14.9 Max: 37.4
Current: -1.6
-1.6
37.4
3-Year EBITDA Growth Rate -8.00
NYSE:TEVA's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NYSE:TEVA: -8.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:TEVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.6  Med: 16.3 Max: 47.4
Current: -8
-9.6
47.4
3-Year EPS without NRI Growth Rate -63.90
NYSE:TEVA's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. NYSE:TEVA: -63.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:TEVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: 16 Max: 119.7
Current: -63.9
-63.9
119.7
GuruFocus has detected 6 Warning Signs with Teva Pharmaceutical Industries Ltd $NYSE:TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:TEVA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF586.5011.947 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NYSE:ZTS, OTCPK:TKPYY, NAS:MYL, OTCPK:SGIOF, OTCPK:ESALF, OTCPK:MKGAY, OTCPK:MTZXF, OTCPK:IPSEY, OTCPK:HLUKF, NYSE:PRGO, OTCPK:SFOSF, OTCPK:APNHF, NYSE:RDY, OTCPK:GZPHY, NYSE:VRX, OTCPK:HYPMY, NYSE:PTHN, OTCPK:HKMPY, OTCPK:RGEDF, NYSE:TARO » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

The Fading Fortunes of John Paulson Hedge fund guru won attention for his strategy during the subprime crisis, but lately he’s been getting attention for the wrong reasons
John Paulson (Trades, Portfolio) was once a darling of Wall Street, having handsomely profited because of his smart bets on the subprime crisis while many of his counterparts suffered. Read more...
Francis Chou Buys Pharmaceutical Stocks, Including Valeant Chou said he is making a 'basket' of the 'attractive' stocks
Francis Chou (Trades, Portfolio)’s Toronto-based fund announced this week that it bought two new drug manufacturers in the first quarter, along with adding to stakes in oil and gas and a notoriously troubled pharmaceutical company. Read more...
Stocks That Fell to 3-Year Lows in the Week of April 14 Teva Pharmaceutical Industries Ltd, Nielsen Holdings PLC, Perrigo Co PLC, and Kimco Realty Corp fell to their respective three-year lows.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA), Nielsen Holdings PLC (NYSE:NLSN), Perrigo Co PLC (NYSE:PRGO), and Kimco Realty Corp (NYSE:KIM) have declined to their three-year lows. Read more...
What Will Make Man Smarter? Companies are increasingly investing in smart drugs
The word "smart" has become a mainstay in every culture across the globe due to the increased use of smart devices. Yet the biggest challenge is making sure that man can keep up with the advances in technology. Are you afraid of AI? Read more...
Risk-Reward With Teva Pharmaceutical With the stock down close to 40% over the last year, is it a buy or a value trap?
As two of its largest guru shareholders, John Paulson (TradesPortfolio) and David Tepper (TradesPortfolio) are dead wrong on Teva Pharmaceutical Industires Ltd. (NYSE:TEVA). Teva is a value trap even if the stock had a short-term price pop. Paulson owns 15.9 million shares, good for 7.36% of his portfolio, while Tepper owns 5.05 million shares, good for 3.25% of his total assets managed. Read more...
23 Questions With the Founder of WayUndervalued.com Are there other sector companies trading similarly? If not, ask yourself why one company would be different
1. How and why did you get started investing? What is your background? Read more...
Valeant: It's Not a Game of Chess- Part I A case study of the rise and fall of Valeant
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...

Ratios

vs
industry
vs
history
PE Ratio 3281.00
NYSE:TEVA's PE Ratio is ranked lower than
100% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.96 vs. NYSE:TEVA: 3281.00 )
Ranked among companies with meaningful PE Ratio only.
NYSE:TEVA' s PE Ratio Range Over the Past 10 Years
Min: 10.49  Med: 20.9 Max: 3470
Current: 3281
10.49
3470
Forward PE Ratio 6.91
NYSE:TEVA's Forward PE Ratio is ranked higher than
94% of the 68 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.46 vs. NYSE:TEVA: 6.91 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 3281.00
NYSE:TEVA's PE Ratio without NRI is ranked lower than
99% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.64 vs. NYSE:TEVA: 3281.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
NYSE:TEVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.49  Med: 20.9 Max: 3470
Current: 3281
10.49
3470
Price-to-Owner-Earnings 20.25
NYSE:TEVA's Price-to-Owner-Earnings is ranked higher than
71% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. NYSE:TEVA: 20.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NYSE:TEVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.02  Med: 16.64 Max: 72.38
Current: 20.25
9.02
72.38
PB Ratio 1.08
NYSE:TEVA's PB Ratio is ranked higher than
87% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NYSE:TEVA: 1.08 )
Ranked among companies with meaningful PB Ratio only.
NYSE:TEVA' s PB Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.11 Max: 2.91
Current: 1.08
0.95
2.91
PS Ratio 1.41
NYSE:TEVA's PS Ratio is ranked higher than
75% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. NYSE:TEVA: 1.41 )
Ranked among companies with meaningful PS Ratio only.
NYSE:TEVA' s PS Ratio Range Over the Past 10 Years
Min: 1.24  Med: 2.63 Max: 4.33
Current: 1.41
1.24
4.33
Price-to-Free-Cash-Flow 9.50
NYSE:TEVA's Price-to-Free-Cash-Flow is ranked higher than
88% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.35 vs. NYSE:TEVA: 9.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NYSE:TEVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.15  Med: 13.58 Max: 32.03
Current: 9.5
7.15
32.03
Price-to-Operating-Cash-Flow 7.47
NYSE:TEVA's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. NYSE:TEVA: 7.47 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NYSE:TEVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.93  Med: 10.81 Max: 22.47
Current: 7.47
5.93
22.47
EV-to-EBIT 65.08
NYSE:TEVA's EV-to-EBIT is ranked lower than
88% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.48 vs. NYSE:TEVA: 65.08 )
Ranked among companies with meaningful EV-to-EBIT only.
NYSE:TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 21.05 Max: 192.9
Current: 65.08
11.4
192.9
EV-to-EBITDA 25.55
NYSE:TEVA's EV-to-EBITDA is ranked lower than
68% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.55 vs. NYSE:TEVA: 25.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
NYSE:TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.5  Med: 14.35 Max: 57.2
Current: 25.55
8.5
57.2
Shiller PE Ratio 14.11
NYSE:TEVA's Shiller PE Ratio is ranked higher than
91% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.91 vs. NYSE:TEVA: 14.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
NYSE:TEVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.23  Med: 27.29 Max: 68
Current: 14.11
12.23
68
Current Ratio 0.93
NYSE:TEVA's Current Ratio is ranked lower than
91% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. NYSE:TEVA: 0.93 )
Ranked among companies with meaningful Current Ratio only.
NYSE:TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.59 Max: 2.95
Current: 0.93
0.9
2.95
Quick Ratio 0.62
NYSE:TEVA's Quick Ratio is ranked lower than
90% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. NYSE:TEVA: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
NYSE:TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.04 Max: 2.19
Current: 0.62
0.62
2.19
Days Inventory 156.20
NYSE:TEVA's Days Inventory is ranked lower than
69% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. NYSE:TEVA: 156.20 )
Ranked among companies with meaningful Days Inventory only.
NYSE:TEVA' s Days Inventory Range Over the Past 10 Years
Min: 156.2  Med: 186.4 Max: 208.14
Current: 156.2
156.2
208.14
Days Sales Outstanding 116.68
NYSE:TEVA's Days Sales Outstanding is ranked lower than
75% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. NYSE:TEVA: 116.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
NYSE:TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 116.68
95.91
153.21
Days Payable 80.10
NYSE:TEVA's Days Payable is ranked higher than
57% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. NYSE:TEVA: 80.10 )
Ranked among companies with meaningful Days Payable only.
NYSE:TEVA' s Days Payable Range Over the Past 10 Years
Min: 78.39  Med: 84.39 Max: 111.41
Current: 80.1
78.39
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.13
NYSE:TEVA's Dividend Yield % is ranked higher than
94% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. NYSE:TEVA: 4.13 )
Ranked among companies with meaningful Dividend Yield % only.
NYSE:TEVA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.66  Med: 2.07 Max: 4.77
Current: 4.13
0.66
4.77
Dividend Payout Ratio 68.00
NYSE:TEVA's Dividend Payout Ratio is ranked lower than
100% of the 406 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. NYSE:TEVA: 68.00 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NYSE:TEVA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.42 Max: 68
Current: 68
0.14
68
3-Year Dividend Growth Rate 2.00
NYSE:TEVA's 3-Year Dividend Growth Rate is ranked lower than
63% of the 302 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.90 vs. NYSE:TEVA: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NYSE:TEVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 23.6 Max: 80.9
Current: 2
-6.7
80.9
Forward Dividend Yield % 4.23
NYSE:TEVA's Forward Dividend Yield % is ranked higher than
93% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.71 vs. NYSE:TEVA: 4.23 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.35
NYSE:TEVA's 5-Year Yield-on-Cost % is ranked higher than
90% of the 846 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. NYSE:TEVA: 6.35 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NYSE:TEVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.02  Med: 3.18 Max: 7.34
Current: 6.35
1.02
7.34
3-Year Average Share Buyback Ratio -2.30
NYSE:TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. NYSE:TEVA: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NYSE:TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.3 Max: 4.6
Current: -2.3
-12.6
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.54
NYSE:TEVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. NYSE:TEVA: 0.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NYSE:TEVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.57 Max: 11.3
Current: 0.54
0.53
11.3
Price-to-Median-PS-Value 0.54
NYSE:TEVA's Price-to-Median-PS-Value is ranked higher than
90% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. NYSE:TEVA: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NYSE:TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.05 Max: 2.21
Current: 0.54
0.34
2.21
Earnings Yield (Greenblatt) % 1.50
NYSE:TEVA's Earnings Yield (Greenblatt) % is ranked lower than
61% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. NYSE:TEVA: 1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NYSE:TEVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 4.75 Max: 8.8
Current: 1.5
0.5
8.8
Forward Rate of Return (Yacktman) % 6.89
NYSE:TEVA's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. NYSE:TEVA: 6.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NYSE:TEVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 22.4 Max: 45.5
Current: 6.89
-2
45.5

More Statistics

Revenue (TTM) (Mil) $22,723.00
EPS (TTM) $ 0.01
Beta0.52
Short Percentage of Float0.00%
52-Week Range $27.60 - 56.44
Shares Outstanding (Mil)1,016.00 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 23,158 22,963 23,631
EPS ($) 4.66 4.60 4.84
EPS without NRI ($) 4.66 4.60 4.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.33%
Dividends per Share ($) 1.36 1.43 1.65

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}